Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NGNE

Neurogene Inc

Jul 26 • 04:00PM ET

44.83

Dollar change +2.13
Percentage change 4.99	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM DWAS VXF KOMP IWO IWN VTWO IWC RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.65	Insider Own	10.33%	Shs Outstand	12.82M	Perf Week	6.08%
Market Cap	581.89M	Forward P/E	-	EPS next Y	-4.25	Insider Trans	0.00%	Shs Float	11.64M	Perf Month	40.05%
Income	-39.03M	PEG	-	EPS next Q	-1.05	Inst Own	83.66%	Short Float	12.35%	Perf Quarter	50.08%
Sales	0.00M	P/S	-	EPS this Y	-241.49%	Inst Trans	-32.38%	Short Ratio	12.06	Perf Half Y	40.09%
Book/sh	13.28	P/B	3.38	EPS next Y	-2.50%	ROA	-26.57%	Short Interest	1.44M	Perf Year	225.80%
Cash/sh	13.06	P/C	3.43	EPS next 5Y	25.10%	ROE	-30.96%	52W Range	12.20 - 53.00	Perf YTD	131.32%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.09%	ROI	-21.39%	52W High	-15.42%	Beta	1.42
Dividend TTM	-	Quick Ratio	14.74	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	267.46%	ATR (14)	3.18
Dividend Ex-Date	-	Current Ratio	14.74	EPS Y/Y TTM	-143.04%	Oper. Margin	0.00%	RSI (14)	61.96	Volatility	5.35% 9.19%
Employees	91	Debt/Eq	0.08	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.14	Target Price	51.80
Option/Short	No / Yes	LT Debt/Eq	0.07	EPS Q/Q	-290.56%	Payout	-	Rel Volume	1.56	Prev Close	42.70
Sales Surprise	-	EPS Surprise	3.29%	Sales Q/Q	-	Earnings	May 10 BMO	Avg Volume	119.24K	Price	44.83
SMA20	10.70%	SMA50	21.01%	SMA200	54.07%	Trades		Volume	185,721	Change	4.99%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-27-24	Initiated	BMO Capital Markets	Outperform	$65
Jun-11-24	Initiated	Robert W. Baird	Outperform	$54
Apr-29-24	Initiated	Leerink Partners	Outperform	$46
Mar-21-24	Initiated	William Blair	Outperform	$61
Jan-08-24	Initiated	H.C. Wainwright	Buy	$45
Jan-05-24	Initiated	Stifel	Buy	$31
Jan-04-24	Initiated	TD Cowen	Outperform

Jul-02-24 07:30AM	Neurogene to Participate in BMO Genetic Medicines Summit (Business Wire) -5.32%
Jul-01-24 07:30AM	Neurogene Announces Addition to Russell 3000 Index (Business Wire) +11.62%
Jun-19-24 09:23AM	Meridian Small Cap Growth Fund Trimmed Neurogene (NGNE) on Share Price Appreciation (Insider Monkey)
Jun-18-24 09:26AM	Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome (Business Wire) -24.20%
Jun-05-24 07:30AM	Neurogene to Participate in Upcoming Conferences (Business Wire)
07:30AM	Loading…
Jun-03-24 07:30AM	Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program (Business Wire)
May-10-24 01:54PM	NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024 (InvestorPlace)
07:30AM	Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates (Business Wire)
May-07-24 06:19AM	Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting (Business Wire)
Apr-22-24 04:36PM	Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting (Business Wire)
Mar-20-24 05:31AM	Neurogene Inc (NGNE) Reports Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
Mar-18-24 04:14PM	Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates (Business Wire) +20.00%
Mar-04-24 07:30AM	Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial (Business Wire) +20.47%
Feb-29-24 07:30AM	Neurogene to Participate in Upcoming Investor Conferences (Business Wire)
Jan-16-24 07:00AM	Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer (Business Wire) +7.27%
07:00AM	Loading…
Jan-05-24 07:00AM	Neurogene Announces Business Update and 2024 Outlook (Business Wire) +6.50%
Dec-19-23 07:00AM	Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million (Business Wire) +8.17%

Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NGNE

Neurogene Inc

Upgrade your FINVIZ experience